Piramal Life Sciences, which has developed a wonder Cancer molecule P276 for treatment of head and neck cancer, will shortly begin Phase 2 clinical trials in India.
"This week, we will start the Phase 2 clincal trial of our head and neck cancer molecule following the Drug Controller's approval," Piramal Life Sciences Executive Director Swati Piramal said.
The molecule has undergone successful Phase 1 clinical trial in Canada.
Phase 1 trial is the first stage of testing in humans.
This phase includes trials designed to assess the safety and tolerability of a drug.
A Phase 2 trial is performed on a larger group and are designed to asses how well the drug works as well as to continue Phase 1 safety assesments on a larger group of volunteers and patients.
"We have been ready since February to start Phase 2 trial, but the go ahead came just now," Piramal said.
In developed countries, approvals come in 28 days, she said, adding here it has taken six months.
